ESSA Pharma tanks after terminating trial for its prostate cancer treatment
koto_feja/E+ via Getty Images
ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer treatment.
The trial tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.
The decision followed an interim review of safety, PK, and efficacy data.
Results showed a higher PSA90 response rate in patients treated with enzalutamide alone than expected based on historical data.Additionally, no clear benefit was seen with the masofaniten-enzalutamide combination over enzalutamide alone.
A futility analysis showed a low likelihood of achieving the study’s primary endpoint. The combination was well-tolerated, with no new safety issues, matching the safety profile from Phase 1 studies.
ESSA also said it will end other clinical studies on masofaniten, both as a monotherapy and in combination with other treatments, to focus resources.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10